Daito Pharmaceutical Co.,Ltd. (TYO:4577)
Japan · Delayed Price · Currency is JPY 1,366.00
-4.00 (-0.29%)
Feb 13, 2026, 3:30 PM JST
Daito Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '25 Nov 30, 2025 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 |
| 51,200 | 50,643 | 46,895 | 45,101 | 43,464 | 48,714 | |
Revenue Growth (YoY) | 8.09% | 7.99% | 3.98% | 3.77% | -10.78% | 8.28% |
Cost of Revenue | 42,176 | 42,005 | 37,056 | 34,770 | 32,005 | 37,922 |
Gross Profit | 9,024 | 8,638 | 9,839 | 10,331 | 11,459 | 10,792 |
Selling, General & Admin | 3,564 | 3,333 | 3,431 | 3,082 | 3,004 | 2,719 |
Research & Development | 2,520 | 2,520 | 2,349 | 1,865 | 1,749 | 2,032 |
Operating Expenses | 6,248 | 6,017 | 5,945 | 5,119 | 4,891 | 4,876 |
Operating Income | 2,776 | 2,621 | 3,894 | 5,212 | 6,568 | 5,916 |
Interest Expense | -135 | -123 | -41 | -12 | -9 | -8 |
Interest & Investment Income | 65 | 64 | 65 | 57 | 55 | 64 |
Earnings From Equity Investments | 126 | 75 | - | - | - | - |
Currency Exchange Gain (Loss) | 53 | 34 | -23 | -91 | 22 | 66 |
Other Non Operating Income (Expenses) | 113 | 33 | 29 | 4 | 93 | 28 |
EBT Excluding Unusual Items | 2,998 | 2,704 | 3,924 | 5,170 | 6,729 | 6,066 |
Gain (Loss) on Sale of Investments | 102 | 409 | 326 | -87 | 47 | 1 |
Asset Writedown | -416 | -384 | -165 | -17 | -56 | -314 |
Other Unusual Items | 228 | 228 | 134 | 11 | - | 120 |
Pretax Income | 2,912 | 2,957 | 4,219 | 5,077 | 6,720 | 5,873 |
Income Tax Expense | 644 | 1,192 | 1,040 | 1,549 | 2,092 | 1,716 |
Earnings From Continuing Operations | 2,268 | 1,765 | 3,179 | 3,528 | 4,628 | 4,157 |
Minority Interest in Earnings | -35 | 143 | 116 | 72 | 40 | 89 |
Net Income | 2,233 | 1,908 | 3,295 | 3,600 | 4,668 | 4,246 |
Net Income to Common | 2,233 | 1,908 | 3,295 | 3,600 | 4,668 | 4,246 |
Net Income Growth | -15.77% | -42.09% | -8.47% | -22.88% | 9.94% | 7.66% |
Shares Outstanding (Basic) | 30 | 30 | 31 | 32 | 31 | 30 |
Shares Outstanding (Diluted) | 30 | 30 | 31 | 32 | 31 | 30 |
Shares Change (YoY) | -2.67% | -3.06% | -0.86% | 3.38% | 1.94% | 6.42% |
EPS (Basic) | 74.32 | 62.72 | 105.00 | 113.82 | 152.45 | 141.36 |
EPS (Diluted) | 74.32 | 62.72 | 105.00 | 113.71 | 152.45 | 141.36 |
EPS Growth | -13.46% | -40.27% | -7.67% | -25.41% | 7.85% | 1.16% |
Free Cash Flow | 5,410 | -892 | -1,038 | -1,350 | -257 | -1,136 |
Free Cash Flow Per Share | 180.05 | -29.32 | -33.08 | -42.65 | -8.39 | -37.82 |
Dividend Per Share | 37.500 | 35.000 | 30.000 | 27.273 | 22.727 | 20.909 |
Dividend Growth | 15.38% | 16.67% | 10.00% | 20.00% | 8.70% | 15.00% |
Gross Margin | 17.63% | 17.06% | 20.98% | 22.91% | 26.36% | 22.15% |
Operating Margin | 5.42% | 5.17% | 8.30% | 11.56% | 15.11% | 12.14% |
Profit Margin | 4.36% | 3.77% | 7.03% | 7.98% | 10.74% | 8.72% |
Free Cash Flow Margin | 10.57% | -1.76% | -2.21% | -2.99% | -0.59% | -2.33% |
EBITDA | 7,135 | 6,953 | 7,553 | 9,082 | 9,881 | 9,070 |
EBITDA Margin | 13.94% | 13.73% | 16.11% | 20.14% | 22.73% | 18.62% |
D&A For EBITDA | 4,359 | 4,332 | 3,659 | 3,870 | 3,313 | 3,154 |
EBIT | 2,776 | 2,621 | 3,894 | 5,212 | 6,568 | 5,916 |
EBIT Margin | 5.42% | 5.17% | 8.30% | 11.56% | 15.11% | 12.14% |
Effective Tax Rate | 22.12% | 40.31% | 24.65% | 30.51% | 31.13% | 29.22% |
Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.